Ascentage Pharma Group International Full Year 2023 Earnings: Misses Expectations

Ascentage Pharma Group International (HKG:6855) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥222.0m (up 5.9% from FY 2022).
• Net loss: CN¥925.6m (loss widened by 4.8% from FY 2022).
• CN¥3.28 loss per share.

6855 Products In Clinical Trials

• Phase I: 6.
• Phase II: 15.

6855 Post-Clinical Trial Products

• Pre-registration: 6.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ascentage Pharma Group International Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 43%. Earnings per share (EPS) also missed analyst estimates by 8.5%.

Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 7.1% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Ascentage Pharma Group International that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.